Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease.
about
Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hostsHost-pathogen interaction in HIV infectionImmune activation and paediatric HIV-1 disease outcomeViremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and functionImmune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?HIV-1 vaccine clinical trials: the Brazilian experience.Host HLA B*allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naïve Ugandans.High CD8+ T cell activation marks a less differentiated HIV-1 specific CD8+ T cell response that is not altered by suppression of viral replicationLimited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals.Interferon-alpha administration enhances CD8+ T cell activation in HIV infectionLack of clinical AIDS in SIV-infected sooty mangabeys with significant CD4+ T cell loss is associated with double-negative T cells.Systems biology of natural simian immunodeficiency virus infectionsHIV-associated chronic immune activation.Immune activation promotes evolutionary conservation of T-cell epitopes in HIV-1.CD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and SwitzerlandComparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque.CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway.HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo.Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial.Reconciling Longitudinal Naive T-Cell and TREC Dynamics during HIV-1 InfectionThirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors.Host genetic determinants of HIV pathogenesis: an immunologic perspectiveReplication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics.A dendrite in every pie: myeloid dendritic cells in HIV and SIV infection.Sex differences in HIV-1-mediated immunopathology.Disease Progression in HIV-1-Infected Viremic Controllers.CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral loadImmune activation and collateral damage in AIDS pathogenesis.Beneficial effects of a combination of Korean red ginseng and highly active antiretroviral therapy in human immunodeficiency virus type 1-infected patientsViremic long-term nonprogressive HIV-1 infection is not associated with abnormalities in known Nef functionsThirty years of the human immunodeficiency virus epidemic and beyond.Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals.What pediatric nonprogressors and natural SIV hosts teach us about HIV.Host and Viral Factors in HIV-Mediated Bystander Apoptosis.Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation.A very particular case of long-term non-progressor: nineteen consecutive years of follow-up in the absence of any detectable HIV-1 viraemia.Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses.Elite control of HIV infection: implications for vaccine designHIV control: Is getting there the same as staying there?
P2860
Q22251065-0F66CE41-F641-4340-B72F-A6FDDD37F780Q27009024-CF45FDA6-41A8-407D-9596-69F11EB3D9C5Q28086888-BED7312A-194B-4EFC-BA85-FA782DD879FEQ28732293-E0E8DA9C-919B-4919-92C8-028997E5FF0CQ30362489-31A4A4E9-61C9-4FC2-ADA7-1DA5E7BC9BAEQ30379462-22BEBAFD-8B5C-450D-AD50-CE814227EB9EQ33399724-3F31EBD4-5DD2-4A50-92DF-842505FEB8CEQ33406497-F72F6E15-20DA-4A99-A16D-3B67F1158813Q34105477-10FA63C3-0976-4C03-9601-A68562C2D471Q34145979-ED8F451F-DC87-44F1-BA4D-01057358E021Q34164295-93AAF212-3079-461C-BDA8-7F8B1FE6061FQ34481980-A50BBC48-F1B2-4AF6-A39B-A6F81FA51931Q34653277-6B2EFCDD-7DD9-4745-A686-281C75A96482Q34657787-92998343-C58C-4BA0-ADC0-76A8F4B81E9AQ34664047-B0DC81D3-4208-489A-98B1-6426325A5806Q35015712-A5DDB5F0-CD68-4D43-B066-3954F92371D1Q35115062-9BF88FBB-89D1-4CCC-A4F1-F23C29DB76EFQ35382501-517318C9-885B-48DE-ABCE-7F7A651A4807Q35904816-5070D92A-794A-441B-827A-30DC6CDE1F0EQ35968508-C2FC735B-EB34-487A-87F0-DD9769284155Q36010933-62370934-4D13-469E-9246-FA0BB94D61BEQ36329596-8C2E7B69-AD7B-4585-B77B-B22A6A0A5F17Q36351352-3CD59E0D-AE49-4D09-B980-BE87E925E732Q36483328-2222A1C3-192A-495A-94B4-C46BC49AEEE0Q36535798-12422780-9A18-4CEA-9F1D-13FB1542947BQ36764788-F61C322D-7368-478F-A16F-883BC1607C9CQ37077305-6EEF0CF3-9205-48A8-B29B-A920149159D8Q37148595-0EF6AABC-D436-461A-9E68-6BE27AEBA571Q37199493-21F2CF99-22B3-4154-9419-D8DD12C23BDDQ37301903-03E9ED9B-02BD-4998-9EEA-F1E178D33DC6Q37590574-4D2B9B52-7595-48BA-8EFA-DDF0F328CD27Q37667360-34C609CA-9577-4720-81D4-6A87422FCD80Q37713470-DE6D74CA-5A69-414F-B657-EADEC2119D47Q38967521-21ECAA57-E7F8-439F-B466-445D121D0C87Q40075506-F5EF1866-40D4-4F6F-BCB0-4C8A8ABCBA66Q42533775-DE2E864C-9A8B-46EF-8B93-9C34FFE8312CQ44833363-906ACA74-DC99-4758-973E-5F172FEE1169Q52625002-8139D38E-7FCC-4FFD-B44B-32DF4B0F853CQ56994404-F240A843-3393-48FD-9C26-2148A2A66E10Q58085173-E3BFC32F-1963-4690-BD3F-5E90E8DDA31C
P2860
Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Low immune activation despite ...... ong-term asymptomatic disease.
@ast
Low immune activation despite ...... ong-term asymptomatic disease.
@en
type
label
Low immune activation despite ...... ong-term asymptomatic disease.
@ast
Low immune activation despite ...... ong-term asymptomatic disease.
@en
prefLabel
Low immune activation despite ...... ong-term asymptomatic disease.
@ast
Low immune activation despite ...... ong-term asymptomatic disease.
@en
P2093
P2860
P356
P1433
P1476
Low immune activation despite ...... ong-term asymptomatic disease.
@en
P2093
Christine A Jansen
David Camerini
Frank Miedema
Hanneke Schuitemaker
Nienke Vrisekoop
Shailesh K Choudhary
Sigrid A Otto
P2860
P304
P356
10.1128/JVI.02663-06
P407
P577
2007-05-30T00:00:00Z